An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer

Small cell lung cancer (SCLC) is a highly proliferative, aggressive form of lung cancer that carries a poor prognosis. Recent approvals with new therapeutic options represent the first in more than a decade for SCLC. Lurbinectedin, a newly approved second-line option, is a synthetic alkaloid that co...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Shetal, Petty, William Jeffrey, Sands, Jacob M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
https://www.ncbi.nlm.nih.gov/pubmed/34104228
http://dx.doi.org/10.1177/17588359211020529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
https://www.ncbi.nlm.nih.gov/pubmed/34104228
http://dx.doi.org/10.1177/17588359211020529

Ejemplares similares